Mass General Hospital

Harvard Medical School

Welcome to the MGH Center for Women’s Mental Health

Welcome to the Massachusetts General Hospital Center for Women’s Mental Health, a perinatal and reproductive psychiatry information center.

This website provides a range of current information including discussion of new research findings in women’s mental health and how such investigations inform day-to-day clinical practice. Despite the growing number of studies being conducted in women’s health, the clinical implications of such work are frequently controversial, leaving patients with questions regarding the most appropriate path to follow. Providing these resources to patients and their doctors so that individual clinical decisions can be made in a thoughtful and collaborative fashion dovetails with the mission of our Center.

We hope you find this website informative and we welcome your comments.

The National Pregnancy Registry for Atypical Antipsychotics:

All pregnant women ages 18-45 are eligible to enroll in the registry. We are currently seeking both controls and those being treated with one or more of the following atypical antipsychotics: 

  • Abilify (aripiprazole)
  • Clozaril (clozapine)
  • Geodon (ziprasidone)
  • Invega (paliperidone)
  • Latuda (lurasidone)
  • Risperdal (risperidone)
  • Saphris (asenapine)
  • Seroquel (quetiapine)
  • Zyprexa (olanzapine)

Register now by calling 1-866-961-2388 and help make the future better for many other women just like you.

This study will involve 3 brief phone interviews over an 8-month period. The National Pregnancy Registry for Atypical Antipsychotics is dedicated to evaluating the safety of atypical antipsychotic medications that may be taken by women during pregnancy to treat a wide range of mood, anxiety, or psychiatric disorders. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics during pregnancy. For more information, please call 1-866-961-2388.

The MGH Center for Women’s Mental Health
Perinatal and Reproductive Psychiatry Program
Simches Research Builiding
185 Cambridge St Suite 2200
Boston, MA 02114

To make an appointment:

Massachusetts General Hospital Clinical Program: (617) 724-7792

Latest News from our Blog

  • The Impact of Infertility Treatment on Mood: Some Women are More Vulnerable

    December 16, 2014

    woman-praying

    While many women complain of psychological distress during infertility treatment, it has been somewhat unclear if the anxiety and depression women may experience is related to having to undergo infertility treatment or to the hormonal agents that are used as part of the treatment, or a combination of the two.   While we know that changing ...

    Read more
  • FDA Finalizes Guidelines for Pregnancy and Lactation Labeling Information

    December 11, 2014

    pills

    Last week, the U.S. Food and Drug Administration (FDA) published a report outlining the new standards for how to present information regarding the safety of medications used during pregnancy and breastfeeding: “The new content and formatting requirements will provide a more consistent way to include relevant information about the risks and benefits of prescription drugs ...

    Read more
  • Vitamin D and Menopausal Symptoms

    December 10, 2014

    older-woman-red-shirt

    A recent study has explored the association between vitamin D levels and vasomotor symptoms in a group of postmenopausal women.

    Read more
  • Medications and Pregnancy: A Focus on the Pharmacokinetics

    November 19, 2014

    We have an abundance of articles which address the impact of psychotropic medications on pregnancy.  Much less research, however, has focused on how pregnancy may affect how these medications work.  Physiologic changes take place during pregnancy which may affect the absorption, distribution, metabolism, and elimination of medications.  These pharmacokinetic changes may result in lower psychotropic ...

    Read more
  • New Guidelines Limit Testosterone Supplements for Women

    November 17, 2014

    clipboard

    Both men and women produce testosterone. The big difference is that the levels are much lower in women, around 15 to 40 ng/dL.  In women, testosterone levels begin to decline gradually after the age of 20. In postmenopausal women, testosterone levels are between 0 and 20 ng/dL.  Various symptoms have been attributed to falling levels ...

    Read more
  • PTSD in Veterans Increases Risk of Preterm Birth

    November 11, 2014

    baby-closeup

    Posttraumatic stress disorder (PTSD) is relatively common among pregnant and postpartum women. The lifetime prevalence of PTSD for women is about 10%.  PTSD is most prevalent among women of childbearing age and PTSD symptoms are common during pregnancy.  Earlier this year, we reported on a study which observed that women with a diagnosis of PTSD ...

    Read more
  • Postpartum Depression and Positive Parenting Practices

    November 10, 2014

    playful

    How does postpartum depression affect a mother’s ability to care for and parent her child?  Various studies have demonstrated that depressed mothers may be less attuned to their children’s needs, either being less responsive to the baby or, in some cases, too intrusive.  Researchers have speculated that this mismatch between mother and baby may contribute ...

    Read more
  • SSRI exposure during pregnancy: What’s enough data?

    October 31, 2014

    pills-hand

    The following post was first published in OB/GYN News. Numerous studies on the reproductive safety of selective serotonin reuptake inhibitors (SSRIs) have been published, particularly over the last decade. With the different methodologies used and often disparate results, the extensive data now available in the medical literature can be overwhelming for clinicians and researchers to sort ...

    Read more
  • Pilot Study: Aripiprazole Added to Antidepressants for Postpartum Depression

    October 27, 2014

    woman-thinking-window

    Augmentation strategies can be used to optimize response in patients with major depressive disorder (MDD) who have not responded adequately to antidepressant monotherapy; however, we have no data on the use of adjunctive treatments in women with postpartum depression (PPD).   A recent study tested the effectiveness of antidepressant augmentation with aripiprazole (Abilify) in a cohort ...

    Read more
  • Older Moms at Higher Risk for Depression

    October 23, 2014

    concerned-mother-baby

    A recent study from Canada has observed higher rates of depression in mothers who have children after the age of 40. The prevalence of depression after delivery was about threefold higher in women aged 40 to 44 years as compared to women aged 30 to 35 years. This relationship was even stronger after controlling for ...

    Read more

Read more from our Blog